Evidence map›Paper›PMID 33799608›Full record

ArticleCells2021

Genetic Deletion of Polo-Like Kinase 2 Induces a Pro-Fibrotic Pulmonary Phenotype.

Theresa A Kant, Manja Newe, Luise Winter, Maximilian Hoffmann, Susanne Kämmerer, Erik Klapproth, Karolina Künzel, Mark P Kühnel, Lavinia Neubert, Ali El-Armouche and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 18 citations in OpenAlex.

  1. Osteopontin in Atrial Fibrillation and Atrial Remodeling.Journal of the American Heart Association · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Polo-like kinase2 regulates renal tubulointerstitial fibrosis via notch signaling pathway in diabetic kidney disease.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Theresa A KantInstitute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany.
Manja NeweInstitute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany.
Luise WinterInstitute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany.
Maximilian HoffmannInstitute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany.ORCID 0000-0003-3427-8409
Susanne KämmererInstitute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany.
Erik KlapprothInstitute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany.
Karolina KünzelInstitute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany.
Mark P KühnelInstitute of Pathology, Hannover Medical School, 30625 Hannover, Germany.
Lavinia NeubertInstitute of Pathology, Hannover Medical School, 30625 Hannover, Germany.
Ali El-ArmoucheInstitute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany.
Stephan R KünzelInstitute of Pharmacology and Toxicology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany.ORCID 0000-0001-6302-1755
Technische Universität Dresden · DEMedizinische Hochschule Hannover · DE

Funding

Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany MeDDrive Start
6 · The paper itself

Abstract

Pulmonary fibrosis is the chronic-progressive replacement of healthy lung tissue by extracellular matrix, leading to the destruction of the alveolar architecture and ultimately death. Due to limited pathophysiological knowledge, causal therapies are still missing and consequently the prognosis is poor. Thus, there is an urgent clinical need for models to derive effective therapies. Polo-like kinase 2 (PLK2) is an emerging regulator of fibroblast function and fibrosis. We found a significant downregulation of

Indexed as

AdultAnimalsCell ProliferationCells, CulturedCollagenFemaleFibroblastsGene DeletionGenetic Predisposition to DiseaseHumansInterleukin-18LungMaleMiceMice, 129 StrainMice, KnockoutCollagenIL18 protein, humanInterleukin-18OsteopontinPLK2 protein, humanProtein Serine-Threonine Kinasesserum-inducible kinaseSPP1 protein, humanfibroblastsPLK2pulmonary fibrosis

Identifiers

PMID33799608
PMCPMC8001503
OpenAlexW3135601565

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.